Compare Incyte Corporation (INCY) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs VanEck Semiconductor ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while VanEck Semiconductor ETF trades at $585. Which is the better fit depends on your goals.
| INCY | SMH | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | — |
52-Week High | $129.93 | $668.91 |
52-Week Low | $81.61 | $286.43 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
SMH trades at $584.83, up 2.71% with a neutral technical signal. Moving averages show bullish momentum while oscillators indicate neutral conditions. Recent institutional activity includes Ferguson Shapiro's $4.53 million investment and Clark Asset Management's 105.8% stake increase. The ETF faces competition from alternative semiconductor funds like CHPY, which some analysts favor for income generation.
Outlook remains balanced with AI spending driving semiconductor demand but increasing competition and tariff risks. The fund's heavy Nvidia concentration presents both opportunity and volatility risk. Technical resistance at $587 could limit near-term gains while support at $560 provides downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
